22 September 2017
News and Views
Links and Services
This week's issue of The Lancet investigates everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumors associated with carcinoid syndrome.
Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown antitumour a
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors